In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation with options such as CPX-351, and the role of stem cell transplantation. He also emphasized the importance of molecular profiling and the integration of targeted therapies, such as FLT3 inhibitors, in both initial and relapse settings.